Skip to content
Clinipace Clinical Research
  • Submit RFP
  • Careers
  • Who We Are
    • About Us
    • Our Culture
    • Leadership Team
    • News and Events
    • Our Investment Partners
    • Code of Conduct
  • Global Reach
  • Therapeutic Areas
  • Solutions
    • Clinical Development
    • Clinical Analytics
    • Clinical Technology and Ecosystem
    • Functional Service Partnership (FSP)
    • Regulatory & Strategic Product Development
  • Knowledge Hub
  • Contact Us

Are Biotech Companies Strong Investments?

Home / Who We Are / News and Events / Are Biotech Companies Strong Investments?

Clinipace CEO, Jason Monteleone, CPA, CMA, MBA, analyzes the increases in capital raised by biotech companies that have gone public, thus improving the economy and patient outcomes in this Contract Pharma article. Read more.

Back to News

  • Who We Are
    • About Us
    • Our Culture
    • Leadership Team
    • News and Events
    • Our Investment Partners
    • Code of Conduct
  • Global Reach
  • Therapeutic Areas
  • Solutions
    • Clinical Development
    • Clinical Analytics
    • Clinical Technology and Ecosystem
    • Functional Service Partnership (FSP)
    • Regulatory & Strategic Product Development
  • Knowledge Hub
  • Contact Us

When you have clinical research and development questions, the answer is Clearly Clinipace.

Get in Touch
About Clinipace
At Clinipace, a global, full-service contract research organization (CRO), our approach to clinical research is personal. We deliver a level of collaboration and flexibility not possible in a traditional CRO environment, with an emphasis on personalized services and solutions, regulatory expertise, and therapeutic leadership. Our mission is to improve the way clinical research is performed in major therapeutic areas including oncology, rare disease, gastroenterology, nephrology, and women’s health. Clinipace strives to impact the future of drug development and health care by combining the most advanced technology and a CHALLENGE ACCEPTED approach.

About dMed-Clinipace
In April 2021, Clinipace & dMed merged creating a differentiated mid-size CRO with the largest Asia-Pacific presence.  We are proud to have such a strong group of global investors focused on improving healthcare outcomes and giving sponsors a better CRO choice.  dMed’s 2019 acquisition of Target Health commenced the process of building a Next Generation global CRO for biotech and pharmaceutical companies.  Our investors have invested over $230M to build the next great global CRO. Additional information on dMed-Clinipace’s key investors can be found here.

dMed’s acquisition of Target Health in 2019 began dMed’s evolution from a local to global CRO.   Target Health LLC is owned by dMedClinical Co. Ltd., a privately held company that is majority owned, operated, managed, and controlled by a U.S. citizen and foreign entities located in the People’s Republic of China.  Dr. Lingshi Tan, is the aforementioned U.S. citizen currently residing in Shanghai, China.  Dr. Tan moved to Shanghai (from New York) to become Pfizer’s VP of Worldwide Development Operations, and Chairman and General Manager of Pfizer (China) Research & Development Co.  Dr. Tan founded dMed in 2016 to satisfy the local demand for a high quality, responsive, flexible CRO.

Global Headquarters

3800 Paramount Pkwy, Suite 100
Morrisville, NC 27560 USA
+1 919-224-8800

Useful Links
  • Solutions
  • Careers
  • Knowledge Hub
  • Contact Us

© 2022 Clinipace. All rights reserved.

  • Privacy Statement
  • GDPR Compliance Commitment
  • Transparency in Coverage
  • Contact Us

Connect

  • Who We Are
    • About Us
    • Our Culture
    • Leadership Team
    • News and Events
    • Our Investment Partners
    • Code of Conduct
  • Global Reach
  • Therapeutic Areas
  • Solutions
    • Clinical Development
    • Clinical Analytics
    • Clinical Technology and Ecosystem
    • Functional Service Partnership (FSP)
    • Regulatory & Strategic Product Development
  • Knowledge Hub
  • Contact Us
  • Submit RFP
  • Careers